AstraZeneca (Netherlands)

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

William R. Hiatt, F. Gerry R. Fowkes, Gretchen Heizer et al. · New England Journal of Medicine · 2016 · 618 citations · Full text

Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis

Karen Melissa Hallow, Gabriel Helmlinger, Peter J. Greasley et al. · Diabetes Obesity and Metabolism · 2017 · 459 citations · Full text

Molecular Pharmacology, Heart Failure Hospitalization, Heart Failure +12

A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi et al. · European Journal of Heart Failure · 2019 · 432 citations · Full text

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

Krzysztof Strojek, Kun‐Ho Yoon, Veronika Hrubá et al. · Diabetes Obesity and Metabolism · 2011 · 409 citations

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Qu Zhang, Jia Luo, Song Wu et al. · Cancer Discovery · 2020 · 323 citations · Full text